EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert Ziegler SE
/ Key word(s): Annual Results
Berlin, March 22, 2024 - Eckert Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared to the previous year, sales increased by € 23.8 million or 11%. EBIT from continuing operations before special items reached € 46.9 million. Net profit for the year amounted to € 26.3 million corresponding to earnings per share of € 1.26. For the 2024 financial year, the Executive Board expects sales of just under € 265 million and EBIT before special items from continuing operations of around € 50 million.
22.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Eckert Ziegler SE |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-0 |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, TecDax, |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1864787 |
End of News | EQS News Service |
|
1864787 22.03.2024 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Stock
With 7 Buy predictions and not the single Sell prediction the community is currently very high on Eckert & Ziegler Strahlen- und Medizintechnik AG.
With a target price of 95 € there is potential for a 134.34% increase which would mean more than doubling the current price of 40.54 € for Eckert & Ziegler Strahlen- und Medizintechnik AG.